HOXC11: A Potential Drug Target and Biomarker (G3227)

Target Name: HOXC11

NCBI ID: G3227

HOXC11

HOXC11: A Potential Drug Target and Biomarker

Homeobox C11 (HOXC11) is a protein that is expressed in a variety of tissues, including the brain, heart, and pancreas. It is a member of the homeobox gene family, which is known for the development and maintenance of tissues during embryonic development. HOXC11 has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, HOXC11 has become a focus of interest for researchers and pharmaceutical companies as a potential drug target or biomarker.

Diseases associated with HOXC11

HOXC11 has been implicated in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the primary goals of cancer research is to identify potential drug targets that can be used to treat cancer. HOXC11 is known to play a role in the development and progression of several types of cancer, including neurobladder cancer, ovarian cancer, and prostate cancer. HOXC11 has also been shown to be involved in the regulation of cell proliferation, which is a key factor in the development of cancer.

Neurodegenerative diseases

HOXC11 has also been implicated in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and are often associated with significant distress and quality of life. HOXC11 has been shown to play a role in the regulation of neurodegeneration, as well as in the development and progression of neurodegenerative diseases.

Autoimmune disorders

HOXC11 has also been implicated in the development and progression of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. HOXC11 has been shown to play a role in the regulation of immune function, which is a key factor in the development and progression of autoimmune disorders.

Potential drug targets

HOXC11 is a protein that has the potential to serve as a drug target or biomarker in a variety of diseases. One of the primary goals of drug development is to identify compounds that can interact with specific drug targets and lead to the treatment of a wide range of diseases. HOXC11 is an attractive target for drug development due to its unique biology and the diverse range of diseases that it is associated with.

In addition to its potential as a drug target, HOXC11 also has the potential to serve as a biomarker for several diseases. As HOXC11 is expressed in a variety of tissues, it can be used as a marker for disease progression, as well as for evaluating the effectiveness of treatments. This makes HOXC11 an attractive target for biomarker research, as it can be used to monitor the effectiveness of drugs in a variety of diseases.

Conclusion

HOXC11 is a protein that has the potential to serve as a drug target or biomarker in a variety of diseases. Its unique biology and association with a wide range of diseases make it an attractive target for drug development and biomarker research. Further research is needed to fully understand the role of HOXC11 in disease development and to identify compounds that can interact with it. If successful, HOXC11 has the potential to revolutionize the treatment of a wide range of diseases.

Protein Name: Homeobox C11

Functions: Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Binds to a promoter element of the lactase-phlorizin hydrolase gene

The "HOXC11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HOXC11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets